Systematic reviews of diagnostic test accuracy (DTA) studies are fundamental to the decision making process in evidence based medicine. Although such studies are regarded as high level evidence, these reviews are not always reported completely and transparently. Suboptimal reporting of DTA systematic reviews compromises their validity and generalisability, and subsequently their value to key stakeholders. An extension of the PRISMA (preferred reporting items for systematic review and meta-analysis) statement was recently developed to improve the reporting quality of DTA systematic reviews. The PRISMA-DTA statement has 27 items, of which eight are unmodified from the original PRISMA statement. This article provides an explanation for the 19 new and modified items, along with their meaning and rationale. Examples of complete reporting are used for each item to illustrate best practices.
Preferred reporting items for systematic review and meta-analysis of diagnostic test accuracy studies (PRISMA-DTA): Explanation, elaboration, and checklist / Salameh, J. -P.; Bossuyt, P. M.; Mcgrath, T. A.; Thombs, B. D.; Hyde, C. J.; Macaskill, P.; Deeks, J. J.; Leeflang, M.; Korevaar, D. A.; Whiting, P.; Takwoingi, Y.; Reitsma, J. B.; Cohen, J. F.; Frank, R. A.; Hunt, H. A.; Hooft, L.; Rutjes, A. W. S.; Willis, B. H.; Gatsonis, C.; Levis, B.; Moher, D.; Mcinnes, M. D. F.. - In: BMJ. BRITISH MEDICAL JOURNAL. - ISSN 0959-8146. - 370:12(2020), pp. 1-17. [10.1136/bmj.m2632]
Preferred reporting items for systematic review and meta-analysis of diagnostic test accuracy studies (PRISMA-DTA): Explanation, elaboration, and checklist
Takwoingi Y.;Rutjes A. W. S.Writing – Review & Editing
;
2020
Abstract
Systematic reviews of diagnostic test accuracy (DTA) studies are fundamental to the decision making process in evidence based medicine. Although such studies are regarded as high level evidence, these reviews are not always reported completely and transparently. Suboptimal reporting of DTA systematic reviews compromises their validity and generalisability, and subsequently their value to key stakeholders. An extension of the PRISMA (preferred reporting items for systematic review and meta-analysis) statement was recently developed to improve the reporting quality of DTA systematic reviews. The PRISMA-DTA statement has 27 items, of which eight are unmodified from the original PRISMA statement. This article provides an explanation for the 19 new and modified items, along with their meaning and rationale. Examples of complete reporting are used for each item to illustrate best practices.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Prisma_EE_bmj.m2632.full.pdf
Open access
Tipologia:
Versione pubblicata dall'editore
Dimensione
279.84 kB
Formato
Adobe PDF
|
279.84 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
